Sélectionner la langue
CD27 Ligand
CD27 Ligand Informations sur la molécule
| Nom anglais | CD70 antigen | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 37 | Alias de la cible | CD70 antigen，Surface Antigen CD70，LPFS3，CD27L，Tumor necrosis factor ligand superfamily member 7，CD27LG，CD27-L，CD70，CD70 Molecule，TNFSF7，Tumor Necrosis Factor (Ligand) Superfamily， Member 7，Tumor Necrosis Factor Ligand 8A，Ki-24 Antigen，TNLG8A，CD27 Ligand |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | CD70 antigen |
| Alias de la cible | CD70 antigen，Surface Antigen CD70，LPFS3，CD27L，Tumor necrosis factor ligand superfamily member 7，CD27LG，CD27-L，CD70，CD70 Molecule，TNFSF7，Tumor Necrosis Factor (Ligand) Superfamily， Member 7，Tumor Necrosis Factor Ligand 8A，Ki-24 Antigen，TNLG8A，CD27 Ligand |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 37 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
CD27 Ligand Liste de produits
- Attribut
Protein (14)
- Bibliothèque de produits
En ligne (14)
- Espèces
Mouse (3)Human (11)
- Étiquette
Mouse IgG Fc Tag (2)His Tag (6)His Tag & Avi Tag (1)Fc Tag (1)His Tag & Flag Tag (2)His Tag & Avi Tag & Flag Tag (1)Llama IgG Fc Tag (1)
- Marqueur
Unconjugated (6)Biotin-labeled (2)FITC Labeled (2)APC Labeled (1)PE Labeled (1)AF647 Labeled (1)AF488 Labeled (1)
Ajouter au panier
Quantité totale14
- 1
- 2
CD27 LigandContexte de la molécule
Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.
CD27 LigandAlias de la molécule
CD70,CD27LG,TNFSF7,TNFSF7G,CD27L
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| CD70 VHH - 01 | Lead | Monoclonal | Nanobody | Hematological Malignancy | Non-hodgkin lymphoma |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms | Details |
| ARX-305 | JNJ-0631; ARX-305; NCB-002 | Phase 2 Clinical | Ambrx Inc | Lymphoma; Neoplasms | Details |
| CD70.CAR NK cell therapy (Bellicum Pharma) | Phase 2 Clinical | Bellicum Pharmaceuticals Inc, The University Of Texas MD Anderson Cancer Center | Hodgkin Disease; Lymphoma, B-Cell | Details | |
| ADI-270 | ADI-270 | Phase 2 Clinical | Adicet Bio Inc | Carcinoma, Renal Cell | Details |
| CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Lymphoma; Solid tumours; Urologic Neoplasms | Details | |
| Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Shanghai Tongji Hospital) | Phase 2 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell | Details | |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CTX-131 | CTX-131 | Phase 2 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Esophageal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Mesothelioma; Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | Details |
| GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, B-Cell; Lymphoma, B-Cell | Details | |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| SEA-CD70 | SEA-CD70; PF-08046040 | Phase 1 Clinical | Seagen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| anti-CD70 CAR T-cell therapy linked with modified IL-8 receptor (University of Florida) | Phase 1 Clinical | University Of Florida | Glioblastoma; Glioma; Ovarian Neoplasms; Pancreatic Neoplasms | Details | |
| CAR BCMA-CD70-T cells therapy (The Fifth Medical Center Of Pla General Hospital) | Phase 1 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Neoplasms, Plasma Cell | Details | |
| Novel CAR-ITNK Cells Targeting CD70 and CLL1 therapy (Tongji Hospital) | Phase 1 Clinical | Tongji Hospital | Leukemia, Myeloid, Acute | Details | |
| TGFBR-2 KO CD70 CAR NK cell therapy (The University Of Texas MD Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Adenocarcinoma, Clear Cell | Details | |
| GEN1160 | GEN-1160; GEN1160 | Phase 1 Clinical | Genmab A/S | Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin; Nasopharyngeal Carcinoma | Details |
| CD70-CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Leukemia, Myeloid, Acute; Lymphoma, T-Cell | Details | |
| Anti-CD70-CAR-T Cell therapy(First Song Biotechnology) | Phase 1 Clinical | Shanghai First Song Therapeutics Co Ltd | Carcinoma, Renal Cell | Details | |
| IB-T101 | Phase 1 Clinical | Inceptor Bio LLC | Carcinoma, Renal Cell | Details | |
| Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Lupus Erythematosus, Systemic; Nephrosis | Details | |
| CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute) | CHT101; CHT-101 | Phase 1 Clinical | Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd | Carcinoma, Renal Cell; Glioma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Bone Marrow Neoplasms; Kidney Neoplasms; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma; Sarcoma; Solid tumours | Details | |
| CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD70-targeted CAR-NKT Cells Therapy (CureGenetics) | CGC729; CGC-729 | Phase 1 Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Carcinoma, Renal Cell; Solid tumours | Details |
| ALLO-329 | ALLO-329 | Phase 1 Clinical | Allogene Therapeutics Inc | Anti-synthetase Syndrome; Dermatomyositis; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Scleroderma, Systemic | Details |
| CD70-CART（Hrain） | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
| Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
| CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Arthritis, Juvenile; Carcinoma, Renal Cell; Dermatomyositis; Genital Neoplasms, Female; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Scleroderma, Systemic; Sjogren's Syndrome; Solid tumours; Thymoma; Thyroid Carcinoma, Anaplastic; Uterine Cervical Neoplasms | Details | |
| IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | Hematologic Neoplasms; Neoplasms; Solid tumours | Details | |
| ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute | Details |
| CD70 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma | Details | |
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| [68Ga]Ga-NOTA-RCCB6 | Clinical | Huashan Hospital | Kidney Neoplasms; Lymphoma | Details | |
| [18F]RCCB6 | Clinical | Huashan Hospital | Kidney Neoplasms | Details | |
| CGC-738 | CGC-738; CGC738 | Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Carcinoma, Renal Cell | Details |
| CD19/CD70 CAR-NK cells therapy (Rongu Biotechnology) | RG-1970 | Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell; Neoplasms | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :